Efficient synthesis of (±)-parasitenone, a novel inhibitor of NF-κB
摘要:
Dehydroxymethylepoxyquinomicin (DHMEQ, 1) is a novel nuclear factor-kappa B (NF-kappa B) inhibitor that inhibits DNA binding of NF-kappa B components including p65. To inspect its biological activity of 1, we synthesized parasitenone (3), possessing the common epoxycyclohexenone moiety of 1. Assessment of the inhibitory activity against NF-kappa B indicated that the epoxycyclohexenone moiety is the most essential element for the NF-kappa B inhibitory activity and the salicylic acid moiety may contribute the binding efficiency and specificity. (C) 2009 Elsevier Ltd. All rights reserved.
Efficient synthesis of (±)-parasitenone, a novel inhibitor of NF-κB
摘要:
Dehydroxymethylepoxyquinomicin (DHMEQ, 1) is a novel nuclear factor-kappa B (NF-kappa B) inhibitor that inhibits DNA binding of NF-kappa B components including p65. To inspect its biological activity of 1, we synthesized parasitenone (3), possessing the common epoxycyclohexenone moiety of 1. Assessment of the inhibitory activity against NF-kappa B indicated that the epoxycyclohexenone moiety is the most essential element for the NF-kappa B inhibitory activity and the salicylic acid moiety may contribute the binding efficiency and specificity. (C) 2009 Elsevier Ltd. All rights reserved.
Dehydroxymethylepoxyquinomicin (DHMEQ, 1) is a novel nuclear factor-kappa B (NF-kappa B) inhibitor that inhibits DNA binding of NF-kappa B components including p65. To inspect its biological activity of 1, we synthesized parasitenone (3), possessing the common epoxycyclohexenone moiety of 1. Assessment of the inhibitory activity against NF-kappa B indicated that the epoxycyclohexenone moiety is the most essential element for the NF-kappa B inhibitory activity and the salicylic acid moiety may contribute the binding efficiency and specificity. (C) 2009 Elsevier Ltd. All rights reserved.